[Ip-health] Cipla’s brave act: Will cancer treatment go the AIDS way?
kumargopakm at gmail.com
Mon Nov 12 08:21:19 PST 2012
Cipla’s brave act: Will cancer treatment go the AIDS way?
*by <http://www.firstpost.com/author/>*Nov 12, 2012
In March, when Indian drug company Cipla cut by three-fourth, the prices of
certain cancer medicines, we called it a game-changer that was similar to
the AIDS-treatment breakthrough the company had achieved a decade ago.
Although Cipla's initiative appeared to have been compelled by the
price-cut of a cancer drug called Nexavar by another Indian company Natco
Pharma, following a compulsory license awarded in its favour by the
government of India; its legendary promoter YK Hamied seized the
opportunity to set off what is now turning out to be a new treatment
chairman and managing director, YK Hamied. Reuters
In an interview with the Forbes magazine in July, Hamied had said that he
would slash the prices of six more cancer drugs. “Drug prices, like water,
eventually (will) find their own level,” he said prophetically.
Three days ago, he followed up on his promise and cut prices, by up to 63
percent, of three vital cancer drugs used in the treatment for lung,
breast, colon, pancreatic and other cancers. The inventor of one of the
drugs is Roche, against which Cipla had won a case in Delhi High court.
Going by his July promise, we could expect three more cancer drugs on
What does it mean for cancer treatment in India?
Quite a lot.
Although the total number of drugs whose prices have been slashed so far
are only six, they are important for the treatment for some of the most
common cancers in India. If the March decision, in which the price of a Rs
2.28 lakh/month drug (Nexavar) was brought down to Rs 6,600/month,
symbolically broke the price barrier in cancer treatment, the subsequent
decision by Cipla to reduce the prices of two more of its medicines had
triggered a cascading effect.
The parallel that Hamied, public health managers and access-to-treatment
activists draw, is the breakthrough that Cipla had achieved in bringing
down the price of AIDS-treatment a decade ago. When it took a few thousand
dollars a year to stay alive with HIV, Hamied's aggressive pursuit to
produce generic versions of anti-retroviral drugs drastically reduced
AIDS-related deaths in India, that too for a few hundred rupees a month.
The prices further fell and subsequently even the second line drugs were
available at highly affordable rates, compared to the dollar prices of
their innovator-versions. Today, Cipla and other Indian generic
manufacturers are the lifeline for millions of people living with HIV in
the poor countries of the world.
The country today produces more than 90 percent of the AIDS-drugs in the
world and Cipla is even facing competition from other generic manufacturers
who are willing to offer rock-bottom rates for national and international
tenders. The AIDS-treatment success story is in fact an India story.
Could cancer be the next Indian success story?
If Cipla continues its aggressive strategy, the AIDS story can be repeated
in cancer as well. It can expand the market by putting more people on
treatment, as in the case of AIDS, prompting others to follow suit. It will
help people affected by cancer not only in India, but also across the
India has about 2.5 million cancer patients. Annually, the country records
about 800,000 new cases and 550,000 deaths. The most common cancers in
India are that of lungs, colon, prostate, bladder, breast and kidney.
Although cancer cure and survival rates have dramatically improved over the
years, in countries such as India treatment is still prohibitively
expensive. One of the reasons is the price of medicines.
It's noteworthy that the current spate of falling prices had begun with the
compulsory license granted to Natco to produce Nexavar against the stiff
opposition of multinational drug company Bayer. With the AIDS example of
the past, the Big Pharma in fact knew that Nexavar could be the beginning
of another attack on its unfair monopoly.
In fact, it was so important for the big drug companies that the Obama
administration, which wants lower prices for Americans, had reportedly
tried to arm-twist India out of its decision.
For a long while now, Hamied has been arguing for a "pragmatic compulsory
licensing policy" by which Indian companies will manufacture generic
versions of lifesaving medicines for which it will pay a reasonable royalty
to the innovator-company.
"The country can't afford monopoly prices that multinationals charge. We're
willing to pay 4 percent on sales as royalty to the innovator company.
Canada had a similar policy under the s91 Bill until 1992, so why this big
fuss today? We have to decide our own destiny. It can't be determined by
Washington or London," he said in his Forbes-interview.
India should not lose the current momentum it has gained on prices of
essential drugs. Pressure from Big Pharma is a constant threat in the form
of bi-lateral treaties, counterfeit legislation and dirty patent tricks
under which they attempt to keep the monopoly of even older medicines.
India has no choice. If the vigilance of patent offices, courts and civil
society is matched by appropriate political will, it can tip the balance to
India's favour. Incidentally, millions of desperately poor people in other
countries will also benefit whether Obama's America will like it or not.
More information about the Ip-health